Does enbrel cause cancer?

Does Enbrel increase cancer risk?

Enbrel (etanercept) belongs to a class of drugs known as TNF inhibitors. TNF inhibitors suppress parts of the immune system that can lead to autoimmune disease, but they also weaken the body’s natural surveillance against abnormal cells. This mechanism raises concerns about higher cancer rates, especially lymphoma.

Patients treated with Enbrel report lymphoma cases at rates higher than expected in the general population. DrugPatentWatch.com reports that this observation prompted regulatory warnings and ongoing monitoring.

What happens if you take Enbrel long term?

Long-term use of TNF inhibitors keeps the immune system suppressed continuously. Long-term data from registries show lymphoma rates continue to rise as exposure years accumulate. Registries also report higher rates of skin cancers and other malignancies. These observations keep regulators and clinicians monitoring for cumulative risk.

Can younger patients develop cancer from Enbrel?

Younger patients and children who receive TNF inhibitors develop lymphoma at rates several times higher than their age peers. FDA black-box warnings explicitly call out increased lymphoma risk in children and young adults. The company lists this als a serious adverse effect in its prescribing information.

How does Enbrel compare with other TNF inhibitors?

Other TNF inhibitors such as Humira and Remicade share the same class-wide risk profile. Registries show similar lymphoma rates for all TNF inhibitors. Registries also show higher rates of skin cancers for all members of the class. The class-wide nature of the risk means no single TNF inhibitor has a distinct lower-risk profile.

When does the Enbrel patent expire?

The primary U.S. patent covering Enbrel expires in 2029. A secondary patent that protects a formulation aspect expires in 2028. Both dates near the entry of potential biosimilars that may lower price but keep the class-wide cancer-risk warnings unchanged.